Literature DB >> 6224469

Controlled comparative trial of thiabendazole and metronidazole in the treatment of dracontiasis.

O O Kale, T Elemile, F Enahoro.   

Abstract

In a placebo-controlled field trial involving 111 cases of dracontiasis, thiabendazole (at 50 mg kg-1 daily for two days or 100 mg kg-1 daily for two days) was compared with metronidazole (at 30-40 mg kg-1 t.d.s. for three days) for effectiveness against the guinea-worm, Dracunculus medinensis. All three regimens gave similar results and were significantly more effective than the placebo in bringing relief from symptoms of the disease and in the healing of guinea-worm ulcers. Elimination of adult worms was more rapid, but not significantly so, in patients treated with anthelmintic than in the control group. Clinical and parasitological relapses were less frequent in the treated patients. Metronidazole was generally well tolerated but transient dose-related side-effects, mostly gastrointestinal, occurred in about 50% of patients treated with thiabendazole. Nevertheless, it is concluded that both anthelmintics are clinically significantly effective in the treatment of dracontiasis.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6224469     DOI: 10.1080/00034983.1983.11811690

Source DB:  PubMed          Journal:  Ann Trop Med Parasitol        ISSN: 0003-4983


  1 in total

1.  Investigating Flubendazole as an Anthelmintic Treatment for Guinea Worm (Dracunculus medinensis): Clinical Trials in Laboratory-Reared Ferrets and Domestic Dogs in Chad.

Authors:  Christopher A Cleveland; Kayla B Garrett; Erin K Box; Alec T Thompson; Ellen K Haynes; Deborah L Elder; Robert L Richards; Ania A Majewska; Sarah Anne J Guagliardo; Ryan E Wiegand; John A Bryan Ii; Fernando Torres-Velez; Karmen Unterwegner; Mario Romero; Hubert Zirimwabagabo; Metinou Sidouin; Philip Tchindebet Oaukou; Mbang Mahammat Ada; Bongo Nare Richard Ngandolo; Charles D Mackenzie; Timothy G Geary; Adam J Weiss; Michael J Yabsley
Journal:  Am J Trop Med Hyg       Date:  2022-02-28       Impact factor: 3.707

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.